Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
EPRX · Why this verdict
Why Eupraxia Pharmaceuticals (EPRX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.9/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts model 143% upside for Eupraxia even though coverage is light, just 9 analysts, and the stock is classified as speculative given the binary nature of biotechnology outcomes. Sentiment breakdown | The stock should move meaningfully toward its modeled upside if clinical or regulatory catalysts play out favorably. | →Stable |
| CounterLight analyst coverage on a speculative biotech means the 143% upside figure carries low statistical reliability and could evaporate on a single downgrade. | ||
Eupraxia's quality score of 1.2 is one of the lowest possible readings, driven by cash-burning operations, no competitive moat, and a weak Piotroski F-Score of 2 out of 9. Quality breakdown | The Piotroski F-Score should climb toward the middle of its range as the company reaches key clinical or commercial milestones. | →Stable |
| CounterPre-revenue clinical-stage biotechs are structurally penalized by quality metrics designed for profitable operating companies. | ||
The stock has failed the engine's momentum gate at 3.8 against a 4.5 threshold, though the engine notes the 200-day moving average is still rising 2.7% over 30 days, framing this as a pullback rather than confirmed weakness. Momentum breakdown | Momentum score should recover above 4.5 as the pullback resolves within the still-rising trend. | →Stable |
| CounterA moving average that is still rising can flatten or roll over if the pullback deepens, turning what looks like a pullback into confirmed weakness. | ||
Eupraxia has missed earnings in 3 of its last 4 reported quarters with an average surprise of -49.7%. Earnings | The beat/miss ratio should improve as clinical trial spending stabilizes relative to estimates. | →Stable |
| CounterClinical-stage biotech earnings are largely driven by R&D spend timing rather than commercial performance, so misses may not reflect the underlying investment thesis. | ||
Analysts model 143% upside for Eupraxia even though coverage is light, just 9 analysts, and the stock is classified as speculative given the binary nature of biotechnology outcomes.
→StableSentiment breakdown
- Expectation
- The stock should move meaningfully toward its modeled upside if clinical or regulatory catalysts play out favorably.
CounterLight analyst coverage on a speculative biotech means the 143% upside figure carries low statistical reliability and could evaporate on a single downgrade.
Eupraxia's quality score of 1.2 is one of the lowest possible readings, driven by cash-burning operations, no competitive moat, and a weak Piotroski F-Score of 2 out of 9.
→StableQuality breakdown
- Expectation
- The Piotroski F-Score should climb toward the middle of its range as the company reaches key clinical or commercial milestones.
CounterPre-revenue clinical-stage biotechs are structurally penalized by quality metrics designed for profitable operating companies.
The stock has failed the engine's momentum gate at 3.8 against a 4.5 threshold, though the engine notes the 200-day moving average is still rising 2.7% over 30 days, framing this as a pullback rather than confirmed weakness.
→StableMomentum breakdown
- Expectation
- Momentum score should recover above 4.5 as the pullback resolves within the still-rising trend.
CounterA moving average that is still rising can flatten or roll over if the pullback deepens, turning what looks like a pullback into confirmed weakness.
Eupraxia has missed earnings in 3 of its last 4 reported quarters with an average surprise of -49.7%.
→StableEarnings
- Expectation
- The beat/miss ratio should improve as clinical trial spending stabilizes relative to estimates.
CounterClinical-stage biotech earnings are largely driven by R&D spend timing rather than commercial performance, so misses may not reflect the underlying investment thesis.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Eupraxia Pharmaceuticals carries large modeled analyst upside typical of a speculative biotech, but a severely weak quality score, a momentum gate failure, and consecutive earnings misses keep the risk high.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.9 |
| MACD | 8.0 |
| OBV | 1.0 |
| MA position | 7.2 |
| Volume | 0.3 |
- ▸Overbought bear rally (RSI 71)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+2.6%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 135%
Insider
5.0/10data confidence 50%Peer rank
4.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.4 |
| growth rank | 5.0 |
Technical
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.5 |
| support resistance | 0.2 |
| 52w position | 4.8 |
Risk (lower is worse)
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| days to cover | 0.0 |
| volatility | 0.0 |
| beta | 5.0 |
| debt equity | 9.9 |
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- ASYMMETRY:7.0>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:35d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.9<4.5
Warning (0)
none
Reward-to-Risk
6.98
Upside
+104.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:3.9<4.5.
The strongest dimensions are Value at 9.0, Sentiment at 7.8, and Growth at 5.0; the weakest are Quality at 1.6, Technical at 1.8, and Catalyst at 2.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 6.98 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Analyst Upside Binary Biotech
Trip ifUpside_pct falls below 60% at the next engine run without a corresponding price increase.
- P2Severely Low Quality Score
Trip ifPiotroski F-Score stays below 3 for 2 more consecutive quarterly updates.
- P3Momentum Gate Failure Within Uptrend Pullback
Trip ifMomentum score stays below 4.5 for 2 more consecutive runs.
- P4Consecutive Earnings Misses
Trip ifMiss_count exceeds 2 misses over the next 3 reported quarters.